Phase 1
Completed N=24
A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerability of Safinamide in Healthy Adult Chinese Volunteers
Healthy
Source: ClinicalTrials.gov NCT03887221 ↗
Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Mar 2023
Primary outcomePrimary: Maximum Safinamide Plasma Concentration (Cmax) — 411.5; 792.1; 465.0; 825.3 nanogram/milliliter (ng/mL)
Summary
This is a Phase I, single center, single and multiple-dose, open-label, randomised, parallel-group, pharmacokinetics, safety and tolerability study. The subjects will be randomised into two study cohorts to receive single and multiple doses of 50 mg safinamide (cohort 1), or single and multiple doses of 100 mg safinamide (cohort 2) as follows:
Cohort 1: One safinamide 50 mg film-coated tablet will be administered on day 1 followed by 7 safinamide 50 mg film-coated tablets in total from day 8 to day 14 and hence administered 1 tablet orally from day 8 to day 14.
Cohort 2: One safinamide 100 mg film-coated tablet will be administered on day 1 followed by 7 safinamide 100 mg film-coated tablets in total from day 8 to day 14 and hence administered 1 tablet orally from day 8 to day 14.
The investigational products will be administered in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
The primary endpoint will assess the pharmacokinetic parameters after single and multiple dose administration of the study drug. The secondary endpoint will provide the safety and tolerability data after single and multiple dose administration of the study drug.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Maximum Safinamide Plasma Concentration (Cmax) |
411.5; 792.1; 465.0; 825.3 | — |
| PRIMARY Time Corresponding to Occurrence of Cmax (Tmax) |
1.500; 1.750; 2.000; 1.508 | — |
| PRIMARY Area Under the Concentration-time Curve From Single-dose Administration to the Last Quantifiable Concentration-time t (AUC0-t) |
11560; 20790; 6652; 12130 | — |
| PRIMARY Area Under the Concentration-time Curve in the Tau Interval (From Single Dose Administration to 24 h Post Dose) (AUC0-24h) |
6291; 11420; 6649; 12090 | — |
| PRIMARY Last Quantifiable Concentration (Clast/Ct) |
23.01; 37.26 | — |
| PRIMARY Terminal Elimination Rate Constant (Kel) |
0.02967; 0.03019 | — |
| PRIMARY Apparent Terminal Elimination Half Life (t1/2) |
23.79; 23.08 | — |
| PRIMARY Percentage of AUC(0-inf) Obtained by Extrapolation (%AUCex) |
6.594; 5.672 | — |
| PRIMARY AUC From Time Zero Extrapolated to Infinity (AUC(0-inf)) |
12380; 22030 | — |
| PRIMARY Apparent Volume of Distribution During Terminal Phase (Vd/F) |
142700; 154800 | — |
| PRIMARY Apparent Clearance Following Oral Administration (CL/F) |
4159; 4634 | — |
| PRIMARY Mean Residence Time (MRT) |
34.65; 33.12 | — |
| PRIMARY Area Under the First Moment of the Concentration-time Curve (AUMC) |
431100; 729400 | — |
| PRIMARY Maximum Safinamide Plasma Concentration at Steady State (Cmax_ss) |
782.8; 1501 | — |
| PRIMARY Time Corresponding to Occurrence of Cmax_ss at Steady State (tmax_ss) |
2.017; 1.483 | — |
| PRIMARY Minimum Observed Concentration at Steady State (Cmin_ss) |
358.3; 583.2 | — |
| PRIMARY Area Under the Concentration-time Curve at Steady State From the Last Dose Administration to the Last Observed Concentration Time t (AUC0-t_ss) |
24170; 42420 | — |
| PRIMARY AUC Over the Dosing Interval at Steady State (AUC0-τ_ss) |
13150; 23100 | — |
| PRIMARY Average Safinamide Plasma Concentration at Steady State(Cave_ss) |
548.0; 962.4 | — |
| PRIMARY Accumulation Ratio, Based on AUC (Racc,AUC) |
2.101; 2.027 | — |
| PRIMARY Accumulation Ratio, Based on Cmax (Racc,Cmax) |
1.939; 1.898 | — |
| PRIMARY Peak-trough Fluctuation Over One Dosing Interval at Steady-state (DF%) |
77.75; 95.17 | — |
| PRIMARY Apparent Volume of Distribution at Steady-state Associated With the Terminal Slope (Vd/F_ss) |
134400; 153100 | — |
| PRIMARY Apparent Total Body Clearance at Steady-state, (CL/F_ss) |
3933; 4426 | — |
| SECONDARY Number of Subjects With Treatment Emergent Adverse Events (TEAEs) |
6; 7; 5; 4; 6; 7 | — |
Eligibility Criteria
Inclusion Criteria
- Informed consent: signed written informed consent before inclusion in the study
- Sex and Age: males and females, 18-45-year old inclusive
- Ethnicity: Chinese
- Weight: body weight ≥ 50 kg;
- Body Mass Index: 19-26 kg/m2 inclusive
- Vital signs: systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89 mmHg, heart rate 50-90 bpm, measured after 5 min at rest in the sitting/supine position
- Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study
- No nicotine addiction (smoker subjects only): ability to abstain for smoking for the duration of the clinical study
- Contraception and fertility (women only): women of child-bearing potential must be using at least one of the following reliable methods of contraception during the study and two weeks post-dose:
- Hormonal oral, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit
- A non-hormonal intrauterine device or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit
- A male sexual partner who agrees to use a male condom with spermicide
- A sterile sexual partner
Women of non-child-bearing potential or in post-menopausal status for at least 1 year will be admitted.
For all women, pregnancy test result must be negative at screening and day -1.
Exclusion Criteria
- Electrocardiogram (12-lead ECG in supine position): clinically significant abnormalities
- Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study
- Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness
- Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the investigator considers may affect the outcome of the study
- Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study; positive result on HIV, hepatitis B (HBV) (except for vaccination), hepatitis C (HCV). Retinal degeneration, uveitis, inherited retinopathy or severe progressive diabetic retinopathy.
- Medications: medications, including over the counter medications, herbal remedies and traditional Chinese remedies for 2 weeks before the start of the study. In particular statins and β-Hydroxy β-methylglutaryl-CoA (HMG-CoA)reductase inhibitors in the 2 weeks before the screening visit; medicinal products that are Breast Cancer Resistance Protein (BCRP) substrates; treatment with morphine or other similar opioids, whose concomitant use with Monoamine oxidase B (MAO-B) inhibitors is contraindicated, Selective serotonin reuptake inhibitors (SSRIs), Serotonin-norepinephrine reuptake inhibitors (SNRIs), tri- or tetracyclic antidepressant, tramadol, pethidine, dextromethorphan, Monoamino oxidase (MAO) inhibitors (e.g. selegiline), meperidine derivatives and antiepileptic drugs in the 4 weeks before the screening visit; treatment with any known enzyme inhibiting or inducing agent within 4 weeks preceding the screening visit. Hormonal contraceptives for women will be allowed
- Investigative drug studies: participation in the evaluation of any investigational product for 3 months before this study
- Blood donation: blood donations or blood components transfusion for 3 months before this study
- Abuse drug, alcohol, caffeine, tobacco: history of drug, alcohol [>1 drink/day for females and >2 drinks/day for males, defined according to the USDA Dietary Guidelines 2015-2020], caffeine (>5 cup
Data sourced from ClinicalTrials.gov (NCT03887221). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.